Clinical Rheumatology

, Volume 37, Issue 4, pp 1017–1024 | Cite as

ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease

  • Airi Nishimi
  • Takeo Isozaki
  • Shinichiro Nishimi
  • Sho Ishii
  • Takahiro Tokunaga
  • Hidekazu Furuya
  • Kuninobu Wakabayashi
  • Tsuyoshi Kasama
Original Article


The “A disintegrin and metalloprotease” (ADAM) family is thought to play an important role in tissue destruction and inflammatory reactions. ADAM-17 was first described as the protease responsible for tumor necrosis factor (TNF)-α shedding. Here, we have shown the expression of ADAM-17 in inflammatory myopathy and demonstrated the role of inflammation in interstitial lung diseases (ILD). ADAM-17 in inflammatory myopathy serum [polymyositis (n = 26), dermatomyositis (n = 34), and clinically amyopathic dermatomyositis (n = 10)] and healthy control (n = 19) was measured using enzyme-linked immunosorbent assay. The relationship between ADAM-17 and clinical data was examined. Finally, we performed immunohistological analysis to investigate the expression of ADAM-17 on the muscles of the inflammatory myopathy patients. ADAM-17 in inflammatory myopathy was significantly higher than that in healthy control (mean ± SEM, 1048 ± 312 and 36 ± 18 pg/ml, respectively; p < 0.05). ADAM-17 in post-treatment with corticosteroid and/or immunosuppressant serum was significantly decreased compared with that in pre-treatment serum (1465 ± 562 and 1059 ± 503 pg/ml, respectively; p < 0.01). ADAM-17 was significantly positively correlated with fractalkine/CX3CL1 and CXCL16. In addition, ADAM-17 in inflammatory myopathy with ILD patients (n = 46) was significantly higher than that in non-ILD patients (n = 24) (1379 ± 454 and 413 ± 226 pg/ml, respectively; p < 0.05). We found the expression of ADAM-17 on muscle biopsy tissue. ADAM-17 is expressed in inflammatory myopathies especially ILD, suggesting that ADAM-17 plays a role in lung fibrosis. ADAM-17 may be a potential target in inflammatory myopathies with ILD.


ADAM-17 CXCL16 Fractalkine/CX3CL1 Inflammatory myopathy Interstitial lung disease 



interstitial lung disease


A disintegrin and metalloprotease


tumor necrosis factor






clinically amyopathic dermatomyositis


amyopathic DM


experimental autoimmune myositis


hypomyopathic dermatomyositis


creatine kinase


enzyme-linked immunosorbent assay


lactate dehydrogenase


fetal bovine serum


phosphate buffered saline


human lung fibroblasts


interleukine-6 receptor


rheumatoid arthritis


synovial tissue








transforming growth factor


major histocompatibility complex I


interferon gamma-induced protein-10/CXCL10



We thank Ms. Takeuchi for performing all ELISAs.

Authors’ contributions

AN performed all assays with assistance from TI, SN, SI, TT, HF, and KW. TI also assisted with the acquisition of data. AN performed the statistical analysis. TI, KW, and TK conceived the study and participated in its design and coordination. TI assisted AN with drafting the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

We obtained written informed consent from all patients who enrolled in the study. The study received approval from the Bio-Ethics Committee of the Department of Medicine, Showa University School of Medicine (No. 1892).




  1. 1.
    Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971–982. CrossRefPubMedGoogle Scholar
  2. 2.
    Callen JP (2000) Dermatomyositis. Lancet 355(9197):53–57. CrossRefPubMedGoogle Scholar
  3. 3.
    Malik A, Hayat G, Kalia JS, Guzman MA (2016) Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol 7:64CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sun WC, Sun YC, Lin H, Yan B, Shi GX (2012) Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol 167(6):1236–1244. CrossRefPubMedGoogle Scholar
  5. 5.
    Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447. CrossRefPubMedGoogle Scholar
  6. 6.
    Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, Song YW (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology 44(10):1282–1286. CrossRefPubMedGoogle Scholar
  7. 7.
    Sakamoto N, Mukae H, Fujii T, Yoshioka S, Kakugawa T, Yamaguchi H et al (2004) Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med 43(9):838–842. CrossRefPubMedGoogle Scholar
  8. 8.
    Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28(5):1005–1012. CrossRefPubMedGoogle Scholar
  9. 9.
    Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, Guo Q, Yang CD, Gu YY, Bao CD, Chen SL (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26(10):1647–1654. CrossRefPubMedGoogle Scholar
  10. 10.
    Isozaki T, Ishii S, Nishimi S, Nishimi A, Oguro N, Seki S, Miura Y, Miwa Y, Oh K, Toyoshima Y, Nakamura M, Inagaki K, Kasama T (2015) A disintegrin and metalloprotease-10 is correlated with disease activity and mediates monocyte migration and adhesion in rheumatoid arthritis. Transl Res 166(3):244–253. CrossRefPubMedGoogle Scholar
  11. 11.
    Dreymueller D, Uhlig S, Ludwig A (2015) ADAM-family metalloproteinases in lung inflammation: potential therapeutic targets. Am J Physiol Lung Cell Mol Physiol 308(4):L325–L343. CrossRefPubMedGoogle Scholar
  12. 12.
    Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM (2007) Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J Biol Chem 282(46):33714–33724. CrossRefPubMedGoogle Scholar
  13. 13.
    Lorenzen I, Trad A, Grotzinger J (2011) Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun 415(2):330–336. CrossRefPubMedGoogle Scholar
  14. 14.
    Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W, Ermert L (2003) In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Cytokine 22(3–4):89–100. CrossRefPubMedGoogle Scholar
  15. 15.
    Moss ML, Sklair-Tavron L, Nudelman R (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4(6):300–309CrossRefPubMedGoogle Scholar
  16. 16.
    Umemura M, Isozaki T, Ishii S, Seki S, Oguro N, Miura Y, Miwa Y, Nakamura M, Inagaki K, Kasama T (2014) Reduction of serum ADAM17 level accompanied with decreased cytokines after abatacept therapy in patients with rheumatoid arthritis. Int J Biomed Sci IJBS 10(4):229–235PubMedGoogle Scholar
  17. 17.
    Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S et al (2014) Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res Ther 14(2):R48CrossRefGoogle Scholar
  18. 18.
    Cao H, Parikh TN, Zheng J (2009) Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 28(8):979–984. CrossRefPubMedGoogle Scholar
  19. 19.
    Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54(4):597–613. CrossRefPubMedGoogle Scholar
  20. 20.
    Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, Fukasawa C, Hara M, Kamatani N (2001) Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J Rheumatol 28(8):1756–1763PubMedGoogle Scholar
  21. 21.
    Sisto M, Lisi S, Lofrumento DD, Ingravallo G, Mitolo V, D'Amore M (2010) Expression of pro-inflammatory TACE-TNF-alpha-amphiregulin axis in Sjogren’s syndrome salivary glands. Histochem Cell Biol 134(4):345–353. CrossRefPubMedGoogle Scholar
  22. 22.
    Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865–874. CrossRefPubMedGoogle Scholar
  23. 23.
    Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 53(12):2196–2203. CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Airi Nishimi
    • 1
  • Takeo Isozaki
    • 1
  • Shinichiro Nishimi
    • 1
  • Sho Ishii
    • 1
  • Takahiro Tokunaga
    • 1
  • Hidekazu Furuya
    • 1
  • Kuninobu Wakabayashi
    • 1
  • Tsuyoshi Kasama
    • 1
  1. 1.Division of Rheumatology, Department of MedicineShowa University School of MedicineTokyoJapan

Personalised recommendations